/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Bond Dealer and Underwriter Others (Securities Business) Derivatives Agents Derivatives Dealer Stock Exchange/Futures Exchange TSFC/IDB Approval and Qualifications Approval and Standards Practice Code of